Patents by Inventor Pere Puigserver
Pere Puigserver has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11247970Abstract: The present invention provides compounds, pharmaceutical compositions and methods for treating and/or preventing a metabolic condition, such as diabetes.Type: GrantFiled: March 21, 2018Date of Patent: February 15, 2022Assignees: Dana-Farber Cancer Institute, Inc., The Scripps Research Institute, The Broad Institute, Inc.Inventors: Pere Puigserver, Kfir Sharabi, Theodore Kamenecka, Patrick Griffin, Stuart L. Schreiber, Roger Schilling, Partha P. Nag, Joshua A. Bittker
-
Publication number: 20200317620Abstract: The present invention provides compounds, pharmaceutical compositions and methods for treating and/or preventing a metabolic condition, such as diabetes.Type: ApplicationFiled: March 21, 2018Publication date: October 8, 2020Applicants: Dana-Farber Cancer Institute, Inc., The Scripps Research InstituteInventors: Pere PUIGSERVER, Kfir SHARABI, Theodore KAMENECKA, Patrick GRIFFIN, Stuart L. SCHREIBER, Roger SCHILLING, Partha P. NAG, Joshua A. BITTKER
-
Publication number: 20090098569Abstract: The invention provides isolated nucleic acid molecules, designated PGC-1b and PGC-1c nucleic acid molecules, which encode novel isoforms of PGC-1 family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1 gene has been introduced or disrupted. The invention still further provides isolated PGC-1 proteins, fusion proteins, antigenic peptides and anti-PGC-1 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: June 20, 2007Publication date: April 16, 2009Applicant: Dana-Farber Cancer Institute, Inc.Inventors: Bruce M. Spiegelman, Guillaume Adelmant, Pere Puigserver
-
Publication number: 20070248590Abstract: Provided herein are methods for using Cdc2-like kinase (Clk) modulators for treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, ocular disorders, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a Clk modulating compound in combination with another therapeutic agent.Type: ApplicationFiled: December 1, 2006Publication date: October 25, 2007Applicant: Sirtris Pharmaceuticals, Inc.Inventors: Jill Milne, Karl Normington, Pere Puigserver, Joseph Rodgers
-
Patent number: 7250283Abstract: The invention provides isolated nucleic acid molecules, designated PGC-1b and PGC-1c nucleic acid molecules, which encode novel isoforms of PGC-1 family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1 gene has been introduced or disrupted. The invention still further provides isolated PGC-1 proteins, fusion proteins, antigenic peptides and anti-PGC-1 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.Type: GrantFiled: July 3, 2002Date of Patent: July 31, 2007Assignee: Dana-Farber Cancer InstituteInventors: Bruce M. Spiegelman, Guillaume Adelmant, Pere Puigserver
-
Patent number: 6908987Abstract: The invention provides isolated nucleic acids molecules, designated PGC-1 nucleic acid molecules, which encode proteins which can modulate various adipocyte-associated activities including, for example, thermogenesis in adipocytes, e.g., brown adipocytes, and adipogenesis. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1 gene has been introduced or disrupted. The invention still further provides isolated PGC-1 proteins, fusion proteins, antigenic peptides and anti-PGC-1 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: May 16, 2003Date of Patent: June 21, 2005Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Bruce M. Spiegelman, Pere Puigserver, Zhidan Wu, Guillaume Adelmant
-
Patent number: 6872391Abstract: The invention provides isolated nucleic acids molecules, designated PGC-1 nucleic acid molecules, which encode proteins which can modulate various adipocyte-associated activities including, for example, thermogenesis in adipocytes, e.g., brown adipocytes, and adipogenesis. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1 gene has been introduced or disrupted. The invention still further provides isolated PGC-1 proteins, fusion proteins, antigenic peptides and anti-PGC-1 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: September 27, 2002Date of Patent: March 29, 2005Assignee: Dana-Farber Cancer InstituteInventors: Bruce M. Spiegelman, Pere Puigserver, Zhidan Wu, Guillaume Adelmant
-
Publication number: 20040254362Abstract: The invention provides isolated nucleic acid molecules, designated PGC-1b and PGC-1c nucleic acid molecules, which encode novel isoforms of PGC-1 family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1 gene has been introduced or disrupted. The invention still further provides isolated PGC-1 proteins, fusion proteins, antigenic peptides and anti-PGC-1 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: July 20, 2004Publication date: December 16, 2004Inventors: Bruce M Spiegelman, Guillaume Adelmant, Pere Puigserver
-
Publication number: 20030229204Abstract: The invention provides isolated nucleic acids molecules, designated PGC-1 nucleic acid molecules, which encode proteins which can modulate various adipocyte-associated activities including, for example, thermogenesis in adipocytes, e.g., brown adipocytes, and adipogenesis. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1 gene has been introduced or disrupted. The invention still further provides isolated PGC-1 proteins, fusion proteins, antigenic peptides and anti-PGC-1 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: May 16, 2003Publication date: December 11, 2003Inventors: Bruce M. Spiegelman, Pere Puigserver, Zhidan Wu, Guillaume Adelmant
-
Publication number: 20030073819Abstract: The invention provides isolated nucleic acids molecules, designated PGC-1 nucleic acid molecules, which encode proteins which can modulate various adipocyte-associated activities including, for example, thermogenesis in adipocytes, e.g., brown adipocytes, and adipogenesis. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1 gene has been introduced or disrupted. The invention still further provides isolated PGC-1 proteins, fusion proteins, antigenic peptides and anti-PGC-1 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: September 27, 2002Publication date: April 17, 2003Applicant: Dana-Farber Cancer InstituteInventors: Bruce M. Spiegelman, Pere Puigserver, Zhidan Wu, Guillaume Adelmant
-
Patent number: 6525178Abstract: The invention provides isolated nucleic acids molecules, designated PGC-1 nucleic acid molecules, which encode proteins which can modulate various adipocyte-associated activities including, for example, thermogenesis in adipocytes, e.g., brown adipocytes, and adipogenesis. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1 gene has been introduced or disrupted. The invention still further provides isolated PGC-1 proteins, fusion proteins, antigenic peptides and anti-PGC-1 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: July 5, 2001Date of Patent: February 25, 2003Assignee: Dana-Farber Cancer InstituteInventors: Bruce M. Spiegelman, Pere Puigserver, Zhidan Wu, Guillaume Adelmant
-
Patent number: 6426411Abstract: The invention provides isolated nucleic acids molecules, designated PGC-1 nucleic acid molecules, which encode proteins which can modulate various adipocyte-associated activities including, for example, thermogenesis in adipocytes, e.g., brown adipocytes, and adipogenesis. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1 gene has been introduced or disrupted. The invention still further provides isolated PGC-1 proteins, fusion proteins, antigenic peptides and anti-PGC-1 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: December 1, 1998Date of Patent: July 30, 2002Assignee: Dana-Farber Cancer InstituteInventors: Bruce M. Spiegelman, Pere Puigserver, Zhidan Wu, Guillaume Adelmant
-
Publication number: 20020082413Abstract: The invention provides isolated nucleic acids molecules, designated PGC-1 nucleic acid molecules, which encode proteins which can modulate various adipocyte-associated activities including, for example, thermogenesis in adipocytes, e.g., brown adipocytes, and adipogenesis. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1 gene has been introduced or disrupted. The invention still further provides isolated PGC-1 proteins, fusion proteins, antigenic peptides and anti-PGC-1 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: July 5, 2001Publication date: June 27, 2002Applicant: Dana-Farber Cancer InstituteInventors: Bruce M. Spiegelman, Pere Puigserver, Zhidan Wu, Guillaume Adelmant
-
Patent number: 6166192Abstract: The invention provides isolated nucleic acids molecules, designated PGC-1 nucleic acid molecules, which encode proteins which can modulate various adipocyte-associated activities including, for example, thermogenesis in adipocytes, e.g., brown adipocytes, and adipogenesis. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1 gene has been introduced or disrupted. The invention still further provides isolated PGC-1 proteins, fusion proteins, antigenic peptides and anti-PGC-1 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: May 29, 1998Date of Patent: December 26, 2000Assignee: Dana-Farber Cancer InstituteInventors: Bruce M. Spiegelman, Pere Puigserver, Zhidan Wu